PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för galanthamine. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

15 hits

Bibliografisk träff 2012-11-12

Structures of human acetylcholinesterase in complex with pharmacologically important ligands.

Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ.

J Med Chem · comparative study; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/jm300871x

Bibliografisk träff 2009-09-24

Magnetic resonance imaging reveals that galantamine prevents structural brain damage induced by an acute exposure of guinea pigs to soman.

Gullapalli RP, Aracava Y, Zhuo J, Helal Neto E, Wang J, Makris G, Merchenthaler I, Pereira EF, Albuquerque EX.

Neurotoxicology · journal article; research support, n.i.h., extramural · DOI 10.1016/j.neuro.2009.09.004

Bibliografisk träff 2009-09-01

Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation.

Moriguchi S, Shioda N, Han F, Yeh JZ, Narahashi T, Fukunaga K.

Hippocampus · research support, non-u.s. gov't; journal article · DOI 10.1002/hipo.20572

Bibliografisk träff 2007-03-31

Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors.

Hansen SB, Taylor P.

J Mol Biol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jmb.2007.03.067

Bibliografisk träff 2006-01-25

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev · meta-analysis; systematic review; systematic-review; journal article · DOI 10.1002/14651858.cd001747.pub3

Bibliografisk träff 2004-12-01

The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design.

Greenblatt HM, Guillou C, Guénard D, Argaman A, Botti S, Badet B, Thal C, Silman I, Sussman JL.

J Am Chem Soc · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/ja0466154

Bibliografisk träff 2004-11-01

Effects of galantamine in patients with mild Alzheimer's disease.

Orgogozo JM, Small GW, Hammond G, Van Baelen B, Schwalen S.

Curr Med Res Opin · clinical trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1185/030079904x12555

Bibliografisk träff 2004-10-18

Galantamine for Alzheimer's disease.

Loy C, Schneider L.

Cochrane Database Syst Rev · meta-analysis; systematic review; journal article · DOI 10.1002/14651858.cd001747.pub2

Bibliografisk träff 2003-01-01

Clinical pharmacokinetics of galantamine.

Farlow MR.

Clin Pharmacokinet · research support, non-u.s. gov't; review; journal article · DOI 10.2165/00003088-200342150-00005

Bibliografisk träff 2002-05-01

The metabolism and excretion of galantamine in rats, dogs, and humans.

Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, Bode W, van Beijsterveldt L, Lavrijsen K, Leempoels J, Van Osselaer N, Van Peer A, Meuldermans W.

Drug Metab Dispos · comparative study; journal article · DOI 10.1124/dmd.30.5.553

Bibliografisk träff 2002-01-01

Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.

Lilienfeld S.

CNS Drug Rev · research-article; review; journal article · DOI 10.1111/j.1527-3458.2002.tb00221.x

Bibliografisk träff 2001-02-01

Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs.

Bartolucci C, Perola E, Pilger C, Fels G, Lamba D.

Proteins · comparative study; journal article · DOI 10.1002/1097-0134(20010201)42:2<182::aid-prot50>3.0.co;2-1

Bibliografisk träff 2000-10-01

Review of the acetylcholinesterase inhibitor galanthamine.

Sramek JJ, Frackiewicz EJ, Cutler NR.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.9.10.2393

Bibliografisk träff 1999-12-01

Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution.

Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL.

FEBS Lett · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/s0014-5793(99)01637-3

Bibliografisk träff 1966-11-01

Clinical experiences with diallyl-nor-toxiferine and the curare antidote galanthamine.

Mayrhofer O.

South Med J · clinical trial; journal article · DOI 10.1097/00007611-196611000-00027